We suspect from prior work in other settings, such as atrial fibrillation, but have not yet observed in the PEPPER trial, that the lowest risk of pulmonary embolism would occur with a factor Xa inhibitor treatment. This evidence concerns the gene F10 and pulmonary embolism.